Research programme: drug discovery - AstraZeneca/Hadasit
Latest Information Update: 26 Sep 2013
At a glance
- Originator AstraZeneca; Hadasit
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Diabetes mellitus; Respiratory tract disorders
Most Recent Events
- 10 Sep 2013 Early research in Cancer, diabetes mellitus and respiratory tract disorders in Israel (unspecified route)